Xeriant Signs Joint Venture with Movychem
Xeriant, Inc. (OTC PINK: XERI) announced a joint venture with Movychem to enhance the development of eco-friendly fire retardant technology, Retacell, targeting aerospace applications.
This 50% stake in Movychem Holdings will enable Xeriant to distribute Retacell in the U.S. and explore additional markets. Retacell is biodegradable, non-toxic, and applicable across various materials, with potential uses in electric aircraft for enhanced safety and durability, aligning with Xeriant’s sustainability strategy.
- Xeriant's joint venture with Movychem allows for immediate focus on aerospace applications and potential for broader market penetration.
- Retacell's eco-friendly and versatile nature positions Xeriant favorably within sustainability trends in the aerospace industry.
- The collaboration aims to exceed Federal Aviation Regulations for safety, enhancing product credibility.
- None.
JV with advanced Material Manufacturer will immediately target potential aerospace applications, with Eco-friendly Fire Protection Technology, and then explore additional Markets
BOCA RATON, Fla., April 01, 2021 (GLOBE NEWSWIRE) -- Xeriant, Inc. (OTC PINK: XERI), a new aerospace technology holding company, announced today that its Czech Republic affiliate, Xeriant Europe s.r.o., has entered into a joint venture with Movychem s.r.o. (“Movychem”), a 27-year-old chemical company based in Slovakia, primarily to further develop applications and new markets for its breakthrough “green” fire retardant and fire resistant products under the brand name Retacell. Under the agreement, Xeriant Europe has a 50 percent stake in Movychem Holdings s.r.o., which will hold all intellectual property rights and patents, as well as exclusivity for distribution of Movychem products in the U.S. market.
“The Movychem JV is consistent with our strategy to acquire technologies that advance sustainability and safety in aerospace and can produce near-term revenue. Many of these innovations have applications in other industries. The new electric aircraft being developed will need to be optimized for aerodynamics and lightweighting, as well as safety, and Movychem’s Retacell has the potential to play a critical role in this mission,” stated Keith Duffy, CEO of Xeriant Aerospace.
Retacell is a breakthrough eco-friendly fire and thermal protection technology that is biodegradable and non-toxic, and can be infused into a variety of plastics, foams, sealants, fillers, adhesives and coatings, as well as textiles and wood-derived products. Movychem is in the process of initiating testing on Retacell treated plastics, textiles, wood-derived materials and carbon fiber. The number of potential applications is almost unlimited in the transportation and construction industries.
The breakthrough thermal and fire protection properties of Retacell could have broad implications in aerospace for the engine, wiring, structural and interior components of flight vehicles, including the insulation of batteries utilized in electric aircraft propulsion systems. Movychem initially plans to test Retacell on the thermoplastics and foams used in aircraft cabin interiors, for floors, ceilings, wall panels and seats. To achieve certification, Movychem plans to work with aircraft materials suppliers, component manufacturers and major airframe manufacturers to produce the safest and most durable materials, with the goal of exceeding all fire, smoke and toxicity requirements according to Federal Aviation Regulations.
“We invested nearly 20 years of R&D in Retacell to make this one of most important advancements in fire and heat protection. Our product is more cost-effective and safer for the environment than competing technologies, and there is greater application flexibility. Teaming up with Xeriant will best position our efforts to not only enter the U.S. market, but to compete for a piece of the global vehicle interiors markets, including aircraft and automobiles, as well as construction materials,” commented JUDr. Lubos Nemecek, Managing Member of Movychem.
About Movychem s.r.o.
Founded in 1993, Movychem s.r.o. (“Movychem”), the creator of Retacell, is a chemical manufacturing company that develops and distributes specialty materials, primarily in Central Europe. Their product line includes sealants, adhesives, fillers, additives, colorants, paints, coatings, fire retardants, and waterproofing materials for a variety of industries and applications. In 2001, Movychem began its research, development and testing of its fire and thermal protection technologies, called Retacell, which led to several global patents. Until 2019, the company was not engaged in the marketing and distribution of Retacell, because its focus was on R&D, testing and certification.
About Xeriant Europe
Xeriant Europe s.r.o., headquartered in Prague, Czech Republic, was founded with the purpose of identifying leading-edge green technologies with applications in aerospace, primarily from the Czech Republic, and promoting them on the world market, especially in the U.S. The company’s focus is on unique products that are either already being sold or are close to commercialization.
About Xeriant
Xeriant, Inc. (d.b.a. Xeriant Aerospace) is a holding and operating company focused on acquiring, developing, and commercializing revolutionary, eco-friendly technologies with applications in aerospace, including innovative aircraft concepts targeting emerging opportunities within the aviation industry. In 2019, Xeriant acquired a unique, scalable, multi-purpose VTOL aerial platform called Halo, which is protected under a broad utility patent. Xeriant is located at the Research Park at Florida Atlantic University in Boca Raton, Florida adjacent to the Boca Raton Airport. The Company is an OTC Markets public company trading under the stock symbol, XERI.
For more information, please go to www.xeriant.com
SAFE HARBOR FORWARD-LOOKING STATEMENTS
In connection with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Xeriant, Inc. is hereby providing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “intends,” “plans,” “believes” and “projects”) may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our expectations concerning our ability to attract investors.
We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
XERIANT, INC. CORPORATE
Investor Relations:
Matt Chipman
(818) 923-5302
IR@xeriant.com
www.xeriant.com
FAQ
What is the joint venture between XERI and Movychem about?
What are the potential applications of Retacell?
What are the benefits of the Retacell technology?
How does this venture affect Xeriant's market strategy?
What is the significance of the partnership with Movychem?
